Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
GSK plc logo

NASDAQ · GSK

GSK plc

Healthcare · Drug Manufacturers - General

$48.68

Up+$0.83 (+1.71%)

Updated Oct 31, 2026, 12:49 AM

SID Score

6.5/10

Composite research score

Smart Money

60/100

Neutral

Market cap
99.39B
P/E ratio
13.41
Dividend yield
3.44%
52-week range
$42.89 – $61.70
Volume
5.61M
Avg. volume
5.18M

Price performance · GSK

GSK price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 29, 2026

GSK closed at $48.68 after 20 trading sessions, up 3.51% for the selected period.

Last close
$48.68
Period change
+3.51%
Period low
$46.27
Period high
$51.21
Daily close
View OHLC price history
GSK OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 29, 2026$48.19$49.11$48.025$48.685.61M
Oct 28, 2026$47.65$49.32$47.355$48.748.12M
Oct 27, 2026$50.80$51.25$50.635$50.944.77M
Oct 26, 2026$50.86$51.235$50.85$51.103.61M
Oct 23, 2026$50.83$50.92$50.29$50.753.18M
Oct 22, 2026$50.29$51.435$49.965$51.214.28M
Oct 21, 2026$50.19$50.445$49.91$50.023.61M
Oct 20, 2026$49.98$51.1205$49.77$50.635.6M
Oct 19, 2026$49.435$49.81$49.26$49.465.37M
Oct 16, 2026$49.615$49.965$49.435$49.516.92M
Oct 15, 2026$49.18$49.84$48.975$49.026.14M
Oct 14, 2026$46.63$47.98$46.55$47.877.09M
Oct 13, 2026$47.09$47.15$46.105$46.275.76M
Oct 12, 2026$46.70$47.085$46.31$46.9210.35M
Oct 9, 2026$46.61$46.82$46.265$46.508.54M
Oct 8, 2026$46.40$46.70$45.825$46.547.73M
Oct 7, 2026$46.92$47.405$46.69$47.025.85M
Oct 6, 2026$46.96$47.01$46.175$46.606.81M
Oct 5, 2026$46.73$46.885$46.33$46.553.48M
Oct 2, 2026$47.08$47.16$46.84$47.035.39M

Latest GSK news

The latest Smart Investors Daily articles mentioning GSK.

Stock researchCompany · Overview

GSK research

Overview

Company profile and research snapshot.

Company profile

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$53.00
Implied upside
—
Analysts
7
GSK recent ratings
DateFirmRatingTarget
Jun 8, 2026DeutscheHold—
May 28, 2026JefferiesBuy—
May 27, 2026DeutscheHold—
May 6, 2026DeutscheHold—
May 6, 2026CitigroupNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

GSK (LSE:GSK) Secures Ex China Rights To KRAS EGFR Cancer Drug

GSK (LSE:GSK) agreed an exclusive global licence with HUTCHMED for KRAS-EGFR antibody drug conjugate HMPL-A830, excluding China. The arrangement grants GSK rights to develop and commercialise HMPL-A830 worldwide outside mainland China, Hong Kong, Macau and Taiwan. HMPL-A830 is described as a first-in-class KRAS-EGFR targeted therapy for solid tumours including colorectal and pancreatic cancer. There is more to GSK than this HMPL-A830 KRAS-EGFR licensing deal with HUTCHMED alone. Our analysis...

Yahoo · Oct 23, 2026

How First In Class Hepatitis B Approval At GSK (LSE:GSK) Has Changed Its Investment Story

GSK received FDA approval for Hibsago, an antisense oligonucleotide injection used with existing antiviral therapy to treat certain adults with chronic hepatitis B without cirrhosis, supported by phase III data showing functional cure in a subset of eligible patients. The product opens a new treatment category within GSK’s liver disease portfolio. It pairs a first in class mechanism with companion diagnostics and may reshape how clinicians manage long term HBV care for carefully selected...

Yahoo · Oct 23, 2026

GSK (LSE:GSK) Stock May Trade At A Discount Despite Hibsago Approval

GSK has delivered strong long term gains for shareholders, and the question now is whether that share price is still in line with what its earnings support. Solid recent news on its drug pipeline adds another layer for you to weigh as you think about what is already reflected in the valuation. Over the past 5 years GSK has returned 55.0%, which puts real pressure on the current earnings profile to justify how far the stock has already come. The recent FDA approval of Hibsago for chronic...

Yahoo · Oct 23, 2026

Why GSK Rose Even Though Profit Fell

GSK just reported higher revenue but a sharply thinner net margin, with profit squeezed even as sales moved up. Investors who held GSK over the past year are up 20.4%, including dividends. That mix of weaker profitability and strong shareholder return is not an obvious pairing. If you had been deciding what to do on 22 October 2025, how would you have evaluated that trade off between earnings pressure and potential upside? The move put GSK in the middle of this trade. Scan 8 healthcare AI...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By